Abatacept for Treating Adults With Giant Cell Arteritis and Takayasu's Arteritis
Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
Giant cell arteritis (GCA) and Takayasu's arteritis (TAK) are diseases that cause swelling of
the arteries in the head, neck, upper body, and arms. TAK specifically affects the aorta, the
largest blood vessel in the body, and its branches. Therapies are available to improve the
symptoms of GCA and TAK, but relapse often occurs, and better treatments are needed.
Abatacept is a drug that interacts with certain cells in the body that are involved with GCA
and TAK. This study will evaluate the effectiveness of abatacept in treating GCA and TAK and
preventing disease relapse.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborators:
Office of Rare Diseases (ORD) Rare Diseases Clinical Research Network The Cleveland Clinic